hit counter
Coherus BioSciences, Inc. (CHRS) Stock News Sentiment & Price - Sentifly
CHRS - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Coherus BioSciences, Inc. (CHRS)

USA
Biotechnology
NASDAQ
CHRS Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
CHRS Latest news
GlobeNewsWire
Neutral
Coherus BioSciences Announces New Employment Inducement Grants
2021-11-10 16:15

REDWOOD CITY, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective Nov. 5, 2021, the compensation committee of the Company's board of directors granted options to purchase an aggregate of 177,500 shares of the common stock of the Company to newly hired employee with a per share exercise price of $17.81, the closing trading price on the grant date. One newly hired Vice President was granted options for 45,000 shares; eleven additional non-officer employees were granted options to purchase an aggregate of 132,500 shares.

Seeking Alpha
Neutral
Coherus BioSciences, Inc. (CHRS) CEO Dennis Lanfear on Q3 2021 Results - Earnings Call Transcript
2021-11-08 23:31

Coherus BioSciences, Inc. (CHRS) CEO Dennis Lanfear on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Negative
Coherus BioSciences (CHRS) Reports Q3 Loss, Misses Revenue Estimates
2021-11-08 19:09

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -22.50% and -5.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Benzinga
Neutral
Recap: Coherus BioSciences Q3 Earnings
2021-11-08 17:39

Coherus BioSciences (NASDAQ:CHRS) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement.

GlobeNewsWire
Neutral
Coherus BioSciences Reports Third Quarter 2021 Results
2021-11-08 16:01

– Key milestones achieved driving near-term commercial product portfolio expansion –

GlobeNewsWire
Neutral
Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022
2021-11-05 08:30

REDWOOD CITY, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the Centers for Medicare & Medicaid Services (“CMS”) will continue to provide increased Medicare reimbursement in the 340B outpatient hospital setting through year-end 2022 for 28 drugs, biologics and devices impacted by the COVID-19 public health emergency, including UDENYCA® (pegfilgrastim-cbqv).

GlobeNewsWire
Neutral
Coherus BioSciences to Report Third Quarter 2021 Financial Results on November 8th
2021-10-29 16:12

REDWOOD CITY, Calif., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2021 financial results will be released after market close on Monday, November 8, 2021. Starting at 5 p.m. ET, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

Zacks Investment Research
Negative
Earnings Preview: Coherus BioSciences (CHRS) Q3 Earnings Expected to Decline
2021-10-28 16:49

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha
Positive
Coherus BioSciences: Dependable Stock With A Possibility Of Appreciation
2021-10-17 12:17

Coherus makes a lot of money from its biosim business. Its foray into R&D is slowly getting derisked with positive data.

GlobeNewsWire
Neutral
Coherus BioSciences Mourns the Passing of Board Member Alan C. Mendelson
2021-10-11 08:30

REDWOOD CITY, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- It is with profound sadness that Coherus BioSciences, Inc. (Nasdaq: CHRS) announces the unexpected passing of board member Alan C. Mendelson. He had been a director of the Company since January 2021 and had previously served as external legal counsel since its founding in 2010.

Loading more news...